

Department of Pathology fully-funded PhD studentships: project proposal form

Pls to complete Parts A & B and to send to your Head of Division by 1 November 2020.  
 Heads of Division to complete Part C and to send to [hod.sec@path.cam.ac.uk](mailto:hod.sec@path.cam.ac.uk)

<b>PART A: PROJECT PROPOSAL</b>	
<b>Division</b>	Immunology
<b>Supervisor</b>	Klaus Okkenhaug
<b>Second supervisor</b> (If supervisor's contract ends before October 2025)	
<b>Project title</b>	Regulation of integrin function on Treg by PI3K
<b>Project abstract for advert</b> (Max 100 words)	Regulatory T cells (Treg) are a major barrier against effective immunotherapy. We have previously shown that inhibiting PI3Kdelta shifts the balance of the immune system by preferentially inhibiting Treg. It remains unknown; however, exactly why tumour-associated Treg are particularly susceptible to PI3Kdelta inhibition. The successful applicant will test the hypothesis that a major function of PI3Kdelta in Tregs is to regulate the integrin LFA-1. We will determine how kinase-dead or hyperactive mutants of PI3Kdelta affect the recruitment and migration of Tregs within tumours.
<b>Keywords</b>  Please provide up to five	Cancer, Immunology, Treg, PI3K,
<b>Full details</b> (Max 250 words)  <b>Will be published on Departmental website; please do not include confidential information</b>	<p>Immunotherapy is revolutionising the treatment of cancer by engaging the immune system to eliminate tumour cells. Regulatory T cells (Treg) are a major barrier against effective immunotherapy. We have previously shown that inhibiting PI3K shifts the balance of the immune system by preferentially inhibiting Treg. It remains unknown; however, exactly why tumour-associated Treg are particularly susceptible to PI3K inhibition.</p> <p>The student will test the hypothesis that a major function of PI3Kdelta in Tregs is to regulate the integrin LFA-1. LFA-1 plays a key role in the recruitment of leukocytes out of circulation and into lymph nodes as well as in interactions with antigen presenting cells (APCs). They will determine how kinase-dead or hyperactive mutants of PI3Kdelta affect the recruitment and migration of Tregs within tumours. They will also monitor how mutations in PI3Kdelta</p>

**Department of Pathology fully-funded PhD studentships: project proposal form**

	<p>affects Treg interactions with dendritic cells in the tumour microenvironment and draining lymph nodes.</p> <p>Using a CRISPR/cas9 screen of proteins that can bind PIP3 (lipid produced by PI3K), we found that Kindlin-3 is an important activator and RASA-3 a key inhibitor of LFA-1. By deleting these proteins in Tregs, we expect to suppress or increase LFA-1-dependent adhesion. Therefore, conditional knock-out models of Kindlin-3 and RASA-3 will enable analysis of the effect of both up and down-regulated LFA-1 adhesion on tumour-associated Tregs. Importantly, these models will allow us the student to assess whether deletion of RASA-3 is sufficient to restore Treg-mediated suppression of tumours in PI3K deficiency.</p> <p>These experiments will elucidate how PI3K-dependent LFA-1 activity controls Treg-mediated suppression of immune responses.</p>
<p><b>Three of your most important publications in support of the proposed project</b></p>	<p>Ali, Khaled, Dalya R. Soond, Roberto Pineiro, Thorsten Hagemann, Wayne Pearce, Ee Lyn Lim, Hicham Bouabe, et al. 'Inactivation of PI(3)K P110<math>\delta</math> Breaks Regulatory T-Cell-Mediated Immune Tolerance to Cancer'. <i>Nature</i> 510, no. 7505 (19 2014): 407–11. <a href="https://doi.org/10.1038/nature13444">https://doi.org/10.1038/nature13444</a>.</p> <p>Garçon, Fabien, and Klaus Okkenhaug. 'PI3K<math>\delta</math> Promotes CD4(+) T-Cell Interactions with Antigen-Presenting Cells by Increasing LFA-1 Binding to ICAM-1'. <i>Immunology and Cell Biology</i> 94, no. 5 (2016): 486–95. <a href="https://doi.org/10.1038/icb.2016.1">https://doi.org/10.1038/icb.2016.1</a>.</p> <p>Lim, Ee Lyn, Fiorella M. Cugliandolo, Dalya R. Rosner, David Gyori, Rahul Roychoudhuri, and Klaus Okkenhaug. 'Phosphoinositide 3-Kinase <math>\delta</math> Inhibition Promotes Antitumor Responses but Antagonizes Checkpoint Inhibitors'. <i>JCI Insight</i> 3, no. 11 (07 2018). <a href="https://doi.org/10.1172/jci.insight.120626">https://doi.org/10.1172/jci.insight.120626</a>.</p>